Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size, Share,...

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Size, Share, and Growth Opportunities 2031

Δημοσιευμένα 2025-03-26 13:51:56

126

"The Chimeric Antigen Receptor (CAR)-T Cell Therapy Market sector is undergoing rapid transformation, with significant growth and innovations expected by 2031. In-depth market research offers a thorough analysis of market size, share, and emerging trends, providing essential insights into its expansion potential. The report explores market segmentation and definitions, emphasizing key components and growth drivers. Through the use of SWOT and PESTEL analyses, it evaluates the sector’s strengths, weaknesses, opportunities, and threats, while considering political, economic, social, technological, environmental, and legal influences. Expert evaluations of competitor strategies and recent developments shed light on geographical trends and forecast the market’s future direction, creating a solid framework for strategic planning and investment decisions.

Get a Sample PDF of Report - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-car-t-cell-therapy-market

Which are the top companies operating in the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market?

The report profiles noticeable organizations working in the water purifier showcase and the triumphant methodologies received by them. It likewise reveals insights about the share held by each organization and their contribution to the market's extension. This Global Chimeric Antigen Receptor (CAR)-T Cell Therapy Market report provides the information of the Top Companies in Chimeric Antigen Receptor (CAR)-T Cell Therapy Market in the market their business strategy, financial situation etc.

Autolus Therapeutics (U.K), CARsgen Therapeutics Co.Ltd. (U.K), Juno Therapeutics, Inc.(U.S), Sorrento Therapeutics, Inc. (U.S)., bluebird bio, Inc. (U.S), CELGENE CORPORATION (U.S), Eureka Therapeutics Inc. (U.S), Avacta Life Sciences Ltd. (U.K), Calyxt Inc. (France), Celyad Oncology SA (Belgium), Fortress Biotech, Inc (U.S.)., IMMUNE THERAPEUTICS, INC (U.S.), Gilead Sciences, Inc. (U.S.), Novartis AG (Switzerland), Alaunos Therapeutics, Inc (U.S.)., Poseida Therapeutics, Inc. (U.S.)

Report Scope and Market Segmentation

Which are the driving factors of the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market?

The driving factors of the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market are multifaceted and crucial for its growth and development. Technological advancements play a significant role by enhancing product efficiency, reducing costs, and introducing innovative features that cater to evolving consumer demands. Rising consumer interest and demand for keyword-related products and services further fuel market expansion. Favorable economic conditions, including increased disposable incomes, enable higher consumer spending, which benefits the market. Supportive regulatory environments, with policies that provide incentives and subsidies, also encourage growth, while globalization opens new opportunities by expanding market reach and international trade.

Chimeric Antigen Receptor (CAR)-T Cell Therapy Market - Competitive and Segmentation Analysis:

**Segments**

- By Target Antigen (CD19, CD22, BCMA, and others)
- By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and others)
- By End User (Hospitals, Clinics, and Research Institutes)

The global chimeric antigen receptor (CAR)-T cell therapy market is segmented based on various factors to provide a comprehensive analysis of the industry landscape. By target antigen, the market is segmented into CD19, CD22, BCMA, and others. CD19 is one of the most commonly targeted antigens in CAR-T cell therapy, especially in treating B-cell malignancies. CD22 is another important target antigen, particularly in cases where CD19 has shown resistance. BCMA targeting is gaining traction in multiple myeloma treatment. By application, the market includes acute lymphoblastic leukemia, diffuse large B-cell lymphoma, multiple myeloma, and other indications. Each application segment represents a specific area of focus for CAR-T cell therapy development and commercialization. By end-user, the market is categorized into hospitals, clinics, and research institutes, reflecting the diverse settings in which CAR-T cell therapy is administered and studied.

**Market Players**

- Novartis AG
- Gilead Sciences, Inc.
- bluebird bio, Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- AbbVie Inc.
- Autolus
- Adaptimmune
- CARsgen Therapeutics

The global landscape of CAR-T cell therapy market players is dynamic and competitive, with several key companies leading the way in innovation and commercialization. Novartis AG and Gilead Sciences, Inc. are among the prominent players in the market, having established CAR-T cell therapies for various indications. bluebird bio, Inc., Bristol-Myers Squibb, and Celgene Corporation are also actively involved in advancing CARNovartis AG is one of the major players in the global CAR-T cell therapy market, with its innovative CAR-T cell therapies approved for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Novartis' Kymriah (tisagenlecleucel) was the first CAR-T cell therapy to receive FDA approval in 2017 and has since been making significant strides in the market. Gilead Sciences, Inc., on the other hand, acquired Kite Pharma in 2017, gaining access to Yescarta (axicabtagene ciloleucel), another approved CAR-T cell therapy for large B-cell lymphoma. This strategic move has positioned Gilead Sciences as a key player in the CAR-T cell therapy market, with a strong portfolio of innovative therapies.

bluebird bio, Inc. is known for its work in developing CAR-T cell therapies targeting multiple myeloma and other hematologic malignancies. The company's investigational therapy, bb2121, has shown promising results in clinical trials and could potentially offer a new treatment option for patients with relapsed/refractory multiple myeloma. Bristol-Myers Squibb and Celgene Corporation have also been actively involved in advancing CAR-T cell therapy research and development, aiming to address unmet medical needs in various cancer types.

AbbVie Inc., Autolus, Adaptimmune, and CARsgen Therapeutics are emerging players in the CAR-T cell therapy market, with a focus on expanding the application of CAR-T cell therapies to other solid tumors beyond hematologic malignancies. AbbVie's collaboration with Teneobio to develop novel CAR-T cell therapies showcases the industry's growing interest in leveraging this technology for broader oncology applications. Autolus and Adaptimmune are also advancing their respective CAR-T cell therapy pipelines, with a strong emphasis on improving safety and efficacy profiles.

Overall, the global CAR-T cell therapy market is characterized by intense competition,The global chimeric antigen receptor (CAR)-T cell therapy market is witnessing significant growth and evolution driven by the increasing prevalence of cancer and the need for more effective treatment options. The segmentation of the market based on target antigens such as CD19, CD22, and BCMA enables a tailored approach to addressing different types of malignancies. The focus on these specific antigens highlights the precision and specificity of CAR-T cell therapies in targeting cancer cells, thus enhancing therapeutic outcomes. Additionally, segmenting the market by application allows for a deeper understanding of how CAR-T cell therapies are being utilized across various types of cancers, including acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and multiple myeloma. This segmentation reflects the diverse applications and potential of CAR-T cell therapy in addressing different indications.

The key market players in the CAR-T cell therapy landscape, including Novartis AG, Gilead Sciences, Inc., bluebird bio, Inc., Bristol-Myers Squibb, and Celgene Corporation, are driving innovation and commercialization in the field. Novartis AG's pioneering CAR-T cell therapy, Kymriah, and Gilead Sciences' Yescarta have set a strong foundation for the market, providing effective treatment options for patients with certain hematologic malignancies. These companies continue to invest in research and development to expand the indications and improve the efficacy of CAR-T cell therapies. bluebird bio, Inc. is also making significant strides in advancing CAR

Explore Further Details about This Research Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Report https://www.databridgemarketresearch.com/reports/global-car-t-cell-therapy-market

Key Benefits for Industry Participants and Stakeholders: –

Industry drivers, trends, restraints, and opportunities are covered in the study.
Neutral perspective on the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market scenario
Recent industry growth and new developments
Competitive landscape and strategies of key companies
The Historical, current, and estimated Chimeric Antigen Receptor (CAR)-T Cell Therapy Market size in terms of value and size
In-depth, comprehensive analysis and forecasting of the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historical data and forecast (2024-2031) of the following regions are covered in Chapters

The countries covered in the Chimeric Antigen Receptor (CAR)-T Cell Therapy Market report are U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, and Rest of the Middle East and Africa

Detailed TOC of Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Insights and Forecast to 2031

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Landscape

Part 05: Pipeline Analysis

Part 06: Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Sizing

Part 07: Five Forces Analysis

Part 08: Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Segmentation

Part 09: Customer Landscape

Part 10: Regional Landscape

Part 11: Decision Framework

Part 12: Drivers And Challenges

Part 13: Chimeric Antigen Receptor (CAR)-T Cell Therapy Market Trends

Part 14: Vendor Landscape

Part 15: Vendor Analysis

Part 16: Appendix

Browse More Reports:

Data Bridge Market Research:

Today's trends are a great way to predict future events!

Data Bridge Market Research is a market research and consulting company that stands out for its innovative and distinctive approach, as well as its unmatched resilience and integrated methods. We are dedicated to identifying the best market opportunities, and providing insightful information that will help your business thrive in the marketplace. Data Bridge offers tailored solutions to complex business challenges. This facilitates a smooth decision-making process. Data Bridge was founded in Pune in 2015. It is the product of deep wisdom and experience.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC: +653 1251 978

Email:- corporatesales@databridgemarketresearch.com
"